There is at present good evidence to support the conclusion that triparanol, or MEK-29. by blocking the synthesis of cholesterol, effectively depresses plasma cholesterol levels in man. 2 ' 3 As shown in figure 1, the major biochemical site at which triparanol inhibits cholesterol synthesis is known, from the studies of Avigan and Steinberg, 4 to be at the last step in the synthetic sequence, namely, that involving the reduction of the 24 double bond of desmosterol to form cholesterol. As a result, significant amounts of desmosterol accumulate in the plasma of patients treated with triparanol and most of the apparent decrease in plasma sterol levels produced by triparanol actually, therefore, represents a replacement of a portion of the plasma cholesterol by desmosterol. It follows that the rationale for employing triparanol, or other drugs which act by blocking cholesterol synthesis at the 24 reductase step, must be largely based on the assumption that desmosterol deposits less readily within atherosclerotic plaques than does cholesterol.
• There is at present good evidence to support the conclusion that triparanol, or MEK-29. by blocking the synthesis of cholesterol, effectively depresses plasma cholesterol levels in man. 2 ' 3 As shown in figure 1 , the major biochemical site at which triparanol inhibits cholesterol synthesis is known, from the studies of Avigan and Steinberg, 4 to be at the last step in the synthetic sequence, namely, that involving the reduction of the 24 double bond of desmosterol to form cholesterol. As a result, significant amounts of desmosterol accumulate in the plasma of patients treated with triparanol and most of the apparent decrease in plasma sterol levels produced by triparanol actually, therefore, represents a replacement of a portion of the plasma cholesterol by desmosterol. It follows that the rationale for employing triparanol, or other drugs which act by blocking cholesterol synthesis at the 24 reductase step, must be largely based on the assumption that desmosterol deposits less readily within atherosclerotic plaques than does cholesterol.
The present study represents an attempt, first, to determine whether significant amounts of desmosterol could be found in the atherosclerotic plaques of patients treated with triparanol; and, second, to assess the relative rates of deposition of desmosterol and cholesterol in experimental atherosclerotic plaques.
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Methods

STUDIES ON VASCULAR TISSUES FROM PATIENTS
Vascular tissues of five patients were obtained at autopsy or operation. Areas of vessel wall showing well developed but uncalcified plaques, with nearby relatively normal intima, were chosen for analysis. All specimens were preserved in 10% formalin at 4° C until analyses wei'c done.
Patient 1 was a 70-year-old white male whose clinical history included symptoms of cerebrovascular atherosclerosis, an abdominal atherosclerotic aneurysm, intermittent claudieation, and a serum cholesterol of 288 mg per cent. He had been treated with triparanol 9 for 9% months at the time of death from cardiac failure secondary to coronary atherosclerosis. Autopsy revealed a large abdominal aneurysm as well as severe generalized atherosclerosis.
Patient 2 was a 72-yoar-old white male who developed angina for the first time in April, 1960. In. September, 1960, he had an episode of severe anterior chest pain diagnosed as subendocardial infarction. Moderate hypereholesterolemia of 314 mg per cent was noted at that time, and he was. therefore, treated with a high polyunsaturated fat diet. In March, 1961, tripnranol was begun at a dose of 250 mg per day. Angina persisted and in May, 1961, the patient once again experienced severe chest pain. The electrocardiogram at that time indicated both an acute and an old subendocardial infarot. Increasingly severe congestive failure intervened and the patient expired suddenly on May 27, 1961. At autopsy evidence of severe widespread atherosclerosis and an old myocardial infarction was found.
Patient 3 was a 43-year-old white female who received triparanol at a dose of 250 mg per day intermittently over a 2-year period for treatment of hypereholesterolemia and recurrent intermittent claudieation in both lower extremities. Intimal tissue from the abdominal aorta was obtained at endarterectomy. Site of action of triparanol (MER-29).
died of a cause unrelated to vascular disease. Analyses of the atherosclerotic plaques of the aorta nre included to demonstrate the absence of desmosterol from the arteries of patients who have not received triparanol.
Patient 5 was a 15-year-old white male who died following trauma and whose nonatherosclerotic vascular tissue was likewise analyzed to provide data on a normal untreated control.
ANIMAL STUDIES
Adult female albino rabbits weighing between 1.7 and 2.2 kilos were employed in this portion of the study. They were fed diets of ground Purina Rabbit Chow to which was added lard in a concentration of 10 per cent. Experimental diets contained in addition either 0.1 or 0.2 per cent triparanol and/or 2 or 5 per cent cholesterol. All animals were fed ad libitum for six weeks. At the end of the experimental period they were killed by an intraperitorieal injection of pentobarbital sodium, their aortas were removed, carefully cleaned of adjacent fat, and analyzed as detailed below. In some cases (experiments shown in figures 4 and 5) the thickened intimal and medial tissue was dissected free of adventia before analysis.
ANALYSIS OF SERUM AND TISSUES
Samples of both serum and tissues were saponified for one hour on a steam-bath with one ml of 90 per cent KOH, one ml of water, and three ml ethanol. Five ml of ethanol were added after saponification and each sample was extracted four times with 30 ml portions of redistilled pentane. The pentanc extracts were backwashed twice with 60 ml of 1:1 ethanol: water and then taken to dryness under nitrogen. Each sample was dissolved in chloroform and an aliquot injected onto a six-foot column of neopentyl glycol succinate, 3 per cent on Gas Chroni P in a Barber-Colman Model 10 gas-liquid chromatography unit equipped with an ionization cell detector. At a column temperature of 200° C and a gas flow of 100 ml per minute, desmosterol could be separated completely from cholesterol. The ehroraatogram of the plasma sterols from a patient treated with triparanol at a dose of 500 mg per day for 23 months illustrates this separation ( fig. 2 ). This method proved capable of detecting quantities of sterols of one tenth mierogram or more. Quantita-
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FIGURE 2
Separation of desmosterol from cholesterol by gasliquid chromatography. Chromatogram of plasma sterols from a patient treated with triparanol at a dose of 500 mg per day for 23 months.
tion of the sterols was carried out according to the method of Bartlet and Smith. 5 The use of gas-liquid ehromatography for the separation and quantitation of sterols has been complicated by the fact that thermal decomposition of sterols may lead to losses during chromatography. 6 In addition, the response of the argon ionization detector may vary from one closely related compound to another. 7 In the case of cholesterol, however, Wilson 8 has demonstrated that a linear relationship exists between the amount of sterol injected onto the chromatographic column and the area-response of the ionization detector. Our findings shown in figure 3 confirm this linear response for amounts of cholesterol varying between 12 and 59 ng; since quantitation of desmosterol by gas-liquid chromatography had not, however, previously been reported, the possibility existed that quantities of this compound might be selectively destroyed during passage through the chromatographic column. While such partial breakdown need not preclude accurate assay of a compound, as demonstrated by the data in figure 3, with the system used here desmosterol produces an identical detector response to that seen with cholesterol and, in addition, over the range of analyses employed, the area of the peaks obtained is related linearly to the amounts of desmosterol injected. Table 1 illustrates the results of analyses of human aortic plaques and relatively uninvolved areas from five patients. As noted, patient 1 received 250 mg of triparanol per day over a 9%-month period; patient 2 was. The desmosterol content varied considerably from plaque to plaque. However, desmosterol made up a small hut significant portion of the sterols of the uninvolved aorta and of each of the plaques examined in the patient treated for 9% months. In the patient who received triparanol for only two months, desmosterol was not found in one of the plaques but this patient's other plaque and both normal areas did contain desmosterol. As can be seen from the ratios of desmosterol to cholesterol presented in the right hand column, higher concentrations of desmosterol tend to 
Results
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Desmosterol Content of Plaque
Relation of area-response of the gas chromatograph-argon ionization detector system to varying quantities of pure cholesterol and desmosterol.
occur at or near the intimal, and to a lesser extent the adventitial, surfaces of the plaques, and in one of the plaques of patient 1 desmosterol was found only in the section nearest the iritima. This finding suggests that the desmosterol probably deposited both by direct penetration of the intimal surface as well as through the vasa vasorum of the media.
Also in table 1 are shown the sterol analyses from two aortic curettings of patient 3, who had been treated with triparanol over a period of two yeai's. Desmosterol: cholesterol ratios of 1.3:100 to 4.2:100 were found, demonstrating once more that desmosterol does contribute to the human atherosclerotic plaque. The accompanying results from two control patients (patients 4 and 5) show, as expected, that the arteries of persons not receiving triparanol contain no desmosterol. The results of analyses of coronary plaques from patient 1 and 2 shown in table 2 illustrate the deposition of desmosterol in this critical location as well.
Desmosterol Content of Human Coronary Arteries
EXPERIMENTAL ATHEROSCLEROSIS; DESMOSTEROL DEPOSITION
While the demonstration that desmosterol accumulates in the atherosclerotic plaques of patients treated with triparanol suggests that this sterol plays a role in the development of such lesions, this finding does not, in itself, indicate whether desmosterol would deposit more or Jess readily than cholesterol in atherosclerotic plaques formed cle novo.
In an attempt to answer this question, rabbits were fed diets containing both cholesterol and triparanol, thereby inducing atherosclerosis experimentally in the presence of an elevated level of plasma desmosterol. A comparison of the ratios of desmosterol to cholesterol in the plasmas, with those in the newly formed plaques of such animals should then provide a measure of the relative rates of deposition of the two sterols within the atherosclerotic plaques.
In the first such experiment rabbits were fed diets containing 10 per cent lard. 2 per cent cholesterol and 0.2 per cent triparauol for a period of six weeks. The animals were then killed, and serum and tissues analyzed as described under "Methods." The data from analyses of two serum samples, whole thoracic aorta and whole abdominal aorta, are shown in table 3. Rabbits 1 and 2, fed a normal diet, had cholesterol values varying from 37 to 81 mg per cent, and no sterol peak other than cholesterol was noted on the gas chromatograms. When triparanol was incorporated into the diet, a desmosterol peak representing from 23 per cent to 50 per cent of the total sterol in the serum appeared (animals 3 and 4). The incorporation of cholesterol alone in the diet resulted, as expected, in an increase in the level of serum cholesterol (animals 5 and 6) but no additional sterols accumulated in the serum. Addition of cholesterol to the triparanol diet resulted in a marked increase in serum cholesterol. Significant levels of desmosterol could none the less be observed in the serum of all rabbits fed the triparanol-eholesterol diet.
The results of analyses of the thoracic and abdominal portions of the aortas demonstrate that in the triparanol-eholesterol treated rab- Photograph of the aorta and results of analyses of individual plaques from a rabbit fed cholesterol (2%) and (0.1%) for 6 weeks. D:C refers to desmosteroleholesterol ratios.
bits, desmosterol was present in concentrations of from 14 to 150 ,ug/g of tissue. More important as indicated by the bold face numbers, in every case the ratio of desmosterol to cholesterol in the aorta was similar to, or greater than, that of the serum, indicating that desmosterol deposited in the aorta at a rate equal to that of cholesterol. It is of interest that in the animals fed triparanol alone (animals 3 and 4) the ratio of desmosterol to cholesterol in the non-atherosclerotic wall was less than that of the final plasma sample, suggesting that in the absence of plaque formation, the structural cholesterol of the aorta does not exchange rapidly with plasma sterols.
In figures 4 and 5 are shown photographs of the aortas and results of analyses of individual plaques from two rabbits fed 5% cholesterol and 0.2% triparanol, or 2% cholesterol and 0.1% triparanol, for six weeks. The ratios of desmosterol to cholesterol in the plaques were comparable to those in the serum.
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indicating again that the rates of deposition of desmosterol equalled those of cholesterol.
It is noteworthy that in the two uninvolved areas examined desmosterol deposition was relatively small or negligible.
Discussion
The results of the gas-liquid chromatographic analyses of arterial sterols, reported here, clearly demonstrate for the first time that small quantities of desmosterol can deposit in the atherosclerotic plaques of human beings who have been treated with triparanol. Prom a clinical standpoint it is of interest that desmosterol was found to be present in the plaques of the coronary vessels as well as in those of the aortas of such patients. Although desmosterol comprised as much as 4% to 5% of the total sterols of s6me of the plaques, this finding does not permit an accurate quantitative evaluation of the role which desmosterol might play in the formation of the HEKNDON, SIPERSTEIN atherosclerotic plaque. It should be emphasized, however, that these concentrations of desmosterol accumulated during a period of only two months (patient 2) to two years (patient 3) of triparanol therapy, and since atherosclerotic plaques undoubtedly formed in these patients over a period of at least 20 to 50 years, the results do suggest a relatively rapid deposition or exchange of desmosterol within the atherosclerotic lesions of man. Our results contrast with those of Blankenhorn, 9 who recently reported that after triparanol therapy, the normal human aorta but not the atherosclerotic plaque contains desmosterol.
In order to obtain a direct estimate of the relative rates of deposition of desmosterol and cholesterol within atherosclerotic plaques, a second study was performed in which atherosclerosis was induced in rabbits by the feeding of both cholesterol and triparanol. A comparison of the ratios of desmosterol to cholesterol in the serum of such rabbits with those in the newly formed plaques provided a measure of the contribution of desmosterol to the plaque formation. The results of such a calculation demonstrate conclusively that desmosterol will deposit in atherosclerotic plaques as readily as will cholesterol, Avigan and Steinberg 10 have also recently reported that in a rabbit fed cholesterol, triparanol, and desmosterol, the deposition of desmosterol in an atherosclerotic plaque occurred to the same extent as did cholesterol. 10 It may be concluded, therefore, that our studies in human beings, taken together with those in the rabbit, strongly suggest that desmosterol is at least as atherogenic as is cholesterol. These results indicate that agents such as triparanol which depress serum cholesterol levels by replacing cholesterol with desmosterol do not provide a rational means of preventing the development of atherosclerosis.
Summary
The role of desmosterol in the production of atherosclerotic plaques has been studied. By means of gas chromatographic analysis, it has been possible for the first time to show that in patients treated with triparanol, even for short periods of time, desmosterol does contribute to the sterol deposition. Furthermore, in the induced atherosclerotic plaques of rabbits desmosterol has been found to deposit at least as readily as does cholesterol. It is concluded from these observations that the replacement of serum cholesterol with desmosterol does not seem to offer a rational approach to the treatment of atherosclerosis.
